Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18106 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Rie Louise Møller Nordestgaard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Foundation Challenge Program, Novo Nordisk Foundation Emerging Investigator Grant.
Abstract (Originalsprache)
Background
Paediatric‐onset and elderly‐onset inflammatory bowel disease (IBD) present unique treatment challenges.
Aims
We investigated treatment patterns following a first and second course of systemic steroids in paediatric‐ and elderly‐onset IBD and compared them to adult‐onset IBD.
Methods
All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 2000 and 2018 were identified through the Danish healthcare registries. Patients were divided into groups based on their age at diagnosis. Kaplan–Meier plots were prepared for medications and surgeries after diagnosis and after the first and second courses of systemic steroids. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using multivariate Cox regression analysis for steroid‐sparing medications.
Results
1851 CD (13%) and 1687 (6%) UC patients were paediatric‐onset, while 2952 (20%) CD and 5812 (23%) UC patients were elderly‐onset. Paediatric‐onset more frequently received immunomodulators [CD: HR: 1.64, CI: 1.52–1.77, UC: HR: 2.29, CI: 2.02–2.61] and biologics [CD: HR: 1.43, CI: 1.25–1.65, UC: HR: 1.27, CI: 0.99–1.64], while elderly‐onset less frequently received immunomodulators [CD: HR: 0.39, CI: 0.35–0.44, UC: HR: 0.58, CI: 0.50–0.67] and biologics [CD: HR: 0.19, CI: 0.14–0.25, UC: HR: 0.36, CI: 0.27–0.48] compared to adult‐onset age groups. After two courses of systemic steroids, elderly‐onset still received less steroid‐sparing medications. High frailty was associated with lower usage of medications for elderly‐onset.
Conclusion
There are significant differences in the use of steroid‐sparing medication between age of onset, even after two courses with systemic steroids. High frailty could account for some of these differences in elderly‐onset IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
- Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
- The Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
- Departments of Epidemiology and Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Rie Louise Møller Nordestgaard, Mads Damsgaard Wewer, Mikkel Malham, Vibeke Wewer, Trine Boysen, Johan Burisch
Förderung
- Novo Nordisk Foundation Challenge Program
- Novo Nordisk Foundation Emerging Investigator Grant
Zitieren
APA
Nordestgaard, R. L. M., Wewer, M. D., Malham, M., Wewer, V., Boysen, T., & Burisch, J. (2024). Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18106
Vancouver
Nordestgaard RLM, Wewer MD, Malham M, Wewer V, Boysen T, Burisch J. Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18106
BibTeX
@article{Nordestgaard2024,
author = {Nordestgaard, Rie Louise Møller and Wewer, Mads Damsgaard and Malham, Mikkel and Wewer, Vibeke and Boysen, Trine and Burisch, Johan},
title = {Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18106}
}
EUVIMED